ArticleBiomedicines2023
The Anti-Virulence Activities of the Antihypertensive Drug Propranolol in Light of Its Anti-Quorum Sensing Effects against
Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Exploring Nonantibiotic Adjuncts: Synergistic Effects of Esmolol and Carvedilol With Tigecycline.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Disclosing New Insights on Pyrazolo[3,4-Journal of microbiology and biotechnology · 2025Article
- Reviving Furosemide as a Metallo-β-Lactamase Inhibitor against MDRJournal of microbiology and biotechnology · 2025Article
- Anti-QS Strategies AgainstMicroorganisms · 2025Review
- Encoding Genes of Metallo β-Lactamases (Health science reports · 2025Review
- Reprofiling lamivudine as an antibiofilm and anti-pathogenic agent against Pseudomonas aeruginosa.AMB Express · 2025Article
- Enoxacin adversely affects Salmonella enterica virulence and host pathogenesis through interference with type III secretion system type II (T3SS-II) and disruption of translocation of Salmonella Pathogenicity Island-2 (SPI2) effectors.Journal of microbiology (Seoul, Korea) · 2025Article
- Nanocomposite alginate hydrogel loaded with propranolol hydrochloride kolliphorDrug delivery and translational research · 2025Article
- Piceatannol: a renaissance in antibacterial innovation unveiling synergistic potency and virulence disruption against serious pathogens.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Sulforaphane Is Not Only a Food Supplement: It Diminishes the Intracellular Survival and Colonization ofACS omega · 2025Article
- Arctigenin from Burdock Root Exhibits Potent Antibacterial and Anti-Virulence Properties againstJournal of microbiology and biotechnology · 2024Article
- Cilostazol is a promising anti-pseudomonal virulence drug by disruption of quorum sensing.AMB Express · 2024Article
- Thymoquinone is a natural antibiofilm and pathogenicity attenuating agent inFrontiers in cellular and infection microbiology · 2024Article
- Investigating Sulforaphane's anti-virulence and anti-quorum sensing properties againstFrontiers in pharmacology · 2024Article
- Redirecting pantoprazole as a metallo-beta-lactamase inhibitor in carbapenem-resistantFrontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of bacterial resistance is an increasing global concern that requires discovering new antibacterial agents and strategies. Bacterial quorum sensing (QS) systems play important roles in controlling bacterial virulence, and their targeting could lead to diminishing bacterial pathogenesis. In this context, targeting QS systems without significant influence on bacterial growth is assumed as a promising strategy to overcome resistance development. This study aimed at evaluating the anti-QS and anti-virulence activities of the β-adrenoreceptor antagonist propranolol at sub-minimal inhibitory concentrations (sub-MIC) against two Gram-negative bacterial models
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.